Researchers have identified an ancient RNA-guided system that can target DNA, potentially expanding the genome-editing toolbox.

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a project that's resulted in new ...

The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing.

We may be starting to get a grasp on what kick-started life on Earth – and it could help us search for it on other planets ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

In this article, we will look at the 10 Best Growth Stocks to Invest in for the Next 10 Years. On March 8, Ben Snider, ...

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...